By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Fresh data on Biotechnology are presented in a new report. According to news reporting from Rotterdam, Netherlands, by NewsRx journalists, research stated, "Prostate cancer is the most common malignancy in the Western world. Patients can be cured only when the tumor has not metastasized outside the prostate."
The news correspondents obtained a quote from the research from Erasmus University Medical Center, "However, treatment with curative intent fails in a significant number of men, often resulting in untreatable progressive disease with a fatal outcome. Oncolytic adenovirus therapy may be a promising adjuvant treatment to reduce local failure or the outgrowth of micrometastatic disease. Within the European gene therapy consortium GIANT, we have developed a novel prostate-specific oncolytic adenovirus: Ad[I/PPT-E1A]. This adenovirus specifically kills prostate cells via prostate-specific replication. This article describes the clinical development of Ad[I/PPT-E1A] with particular reference to the preclinical safety assessment of this novel virus. The preclinical safety assessment involved an efficacy study in a human orthotopic xenograft mouse model, a specificity study in human primary cells, and a toxicity study in normal mice. These studies confirmed that Ad[I/PPT-E1A] efficiently kills prostate tumor cells in vivo, is not harmful to other organs, and is well tolerated in mice after systemic delivery."
According to the news reporters, the research concluded: "The safety, as well as the immunological effects of Ad[I/PPT-E1A] as a local adjuvant therapy, will now be studied in a phase I dose-escalating trial in patients with localized prostate cancer who are scheduled for curative radical prostatectomy and can be used as an updated paradigm for similar therapeutic viruses."
For more information on this research see: Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer. Human Gene Therapy Clinical Development, 2014;25(1):7-15 (see also Biotechnology).
Our news journalists report that additional information may be obtained by contacting E. Schenk, 1 Dept. of Urology, Erasmus MC , 3000 CA Rotterdam, Netherlands. Additional authors for this research include M. Essand, R. Kraaij, R. Adamson, N.J. Maitland and C.H Bangma.
Keywords for this news article include: Biotechnology, Europe, Oncology, Rotterdam, Netherlands, Therapeutics, Prostate Cancer, Pre Trial Research, Cancer Gene Therapy, Prostatic Neoplasms, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC